Compare Mesoblast Limited (MESO) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs TKO Group Holdings Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while TKO Group Holdings Inc trades at $181.02 (market cap $13.28B). The key difference: TKO Group Holdings Inc is far larger — about 7.6× Mesoblast Limited's market cap, and TKO Group Holdings Inc pays a 1.74% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and TKO Group Holdings Inc for 30 Days on average.
| MESO | TKO | |
|---|---|---|
Market Cap | $1.75B | $13.28B |
Volume | 239,027 | 857,653 |
Sector | Health | Media |
52-Week High | $20.96 | $224.96 |
52-Week Low | $13.19 | $175.58 |
Typical Hold Time | 14 Days | 30 Days |
Enterprise Value | $1.83B | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
TKO trades at $178.64, up 1.24% on the day but near recent lows, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth is solid, with 2026 projected at $5.3B, though net margins remain thin at 4.33%. A quarterly dividend of $0.79 was declared for payment in September 2026.
The stock presents a contrast between strong analyst bullishness (89% buy rating, $227 consensus target) and current technical weakness. Upside hinges on execution of media rights monetization and live event growth, while risks include competitive pressures and margin sustainability. The valuation at a P/E of 63.73 demands high future earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
